

# COMPLEX SCIENCE. SIMPLE FORM.



A first-in-class medicinal product for CUD.

*Supporting the clinical management of cannabis-use disorder*



# CANNABIS USE DISORDER (CUD)



Most widely used  
illicit drug  
worldwide. 224M

(UNODC, 2025)



1 in 10 cannabis  
users develops  
CUD

(UNODC, 2025)



Most commonly used  
illicit drug among  
teenagers

(EUDA, 2025)



No pharmaceutical  
treatment  
available

(EUDA, 2025)

# PHARMA-GRADE CESSATION GUM



Benchmark  
Nicotine gum



Precise dose  
Controlled release



European  
Pharmacopoeia  
Compliant



Therapy  
adjunct

# Spain is the regulatory gateway (RD 903/2025)



12.574 PATIENTS

SOM €16.72 M



106.000 PATIENTS

SAM €140.98 M



24.4M PATIENTS

TAM €32.45 BILLION

Market estimates based on  
official treatment-entry data

(OEDA 2024 · EUDA 2025 · UNODC 2025)

Evidence-driven  
regulation

(RD 903/2025)

Benchmark from approved  
nicotine-gum posology

(AEMPS-CIMA)

# PHARMACEUTICAL CONVERSION PROCESS

From plant to medicine — by MFD Technology



## THE PLANT

- Standardized cannabis flower
- Certified genetics
- Controlled cannabinoid profile



## MFD TECHNOLOGY


- Physical–chemical transformation
- Standardization–quantification
- Stability–quality control



## THE MEDICINAL PRODUCT

- Chewing-gum dosage form
- Single-dose, buccal use
- Full spectrum profile

# One clinical milestone unlocking 2 complementary paths



# COMPETITIVE LANDSCAPE: MFD GUM



## CANNABIS OILS

Inconsistent dosing,  
low bioavailability,  
unpleasant taste.



## ORAL SPRAYS

Limited efficacy,  
isolated compounds,  
significant side effects.




## VAPING & SMOKING

Lung damage,  
dependence risk, social  
stigma, institutional  
rejection.

No competitor offers a full-spectrum, monodose medicine validated by the European Pharmacopoeia.

# From Regulation to Clinical Execution



CT: Clinical Trial

PK: Pharmacokinetic evaluation

Ph. Eur.: European Pharmacopoeia

GMP: Good Manufacturing Practice


# OPERATIONALLY LED. EQUITY COMMITTED. INDUSTRY BACKED.

## CORE OPERATING TEAM (Active in the project · Shareholders)



**David Molinero — CEO**  
Founder

Regulatory strategy ·  
Clinical pathway design  
Biotech entrepreneur



**Silvia Fernández — QP**  
Technical Director

Ph. Eur.-grade formulation lead  
GMP & quality systems



**Dr. Gualberto Díaz — CMO**  
Medical Director

Clinical development specialist  
Investigator-led trial design & execution



**Mario Alfonso — CFO**  
Director of Finance


Fundraising · Financial structuring  
Investor relations

## STRATEGIC INDUSTRIAL SHAREHOLDERS



**Enrique Corral**

CEO Valtria  
GMP infrastructures leader  
Industrial pharma scale-up



**Antoni Hereu**

Former General Manager –  
Medicated gum pharmaceutical laboratory  
Global pharma operations

# INTEGRATED DEVELOPMENT & MANUFACTURING ECOSYSTEM



## PHYTOPLANT RESEARCH

Licensed cannabis API production  
Clinical-grade cannabinoid supply



## CAFOSA GUM

Pharmaceutical chewing-gum technology  
Industrial gum-base expertise



## UB-SDM

Ph. Eur.-grade formulation development  
Preclinical and GMP-enabled capabilities

## Round

**€500K**

Capital to raise

**€4,5M**

Pre-money valuation

**€100K**

Minimum ticket  
(~2% equity)

**10%**

Equity offered

## PHASE I CLINICAL TRIAL

Capital raised will fund the first-in-human study.

### Phase I will:

- Validate safety and pharmacokinetics
- De-risk the CUD therapeutic program
- Enable Phase II fundraising
- Increase company valuation
- Activate the CDMO revenue pathway

mfdevelopments.com  
info@mfdevelopments.com



Medical Flowers Developments (MFD)